P.V. Gangurde

Acid-related disorders, including gastro esophageal reflux disease (GERD), duodenal ulcers, and gastric ulcers, are managed by H2 receptor antagonists and proton pump inhibitors (PPIs). PPIs represent first choice for treating acid-peptic ulcers inhibits the gastric- H+/ K+ -ATPase through covalent binding to cysteine residues of the proton pump. Achlorhydria and acute renal failure are the most common drawbacks. A reversible acid pump antagonist (APAs), currently in clinical trial removes these problems. The APAs are the conceivable future drugs for the treatment of acid-peptic disorders.